Investment Counsel Inc. reduced its position in Bristol-Myers Squibb Co (NYSE:BMY) by 5.1% in the fourth quarter, Holdings Channel reports. The fund owned 25,292 shares of the biopharmaceutical company’s stock after selling 1,350 shares during the period. Investment Counsel Inc.’s holdings in Bristol-Myers Squibb were worth $1,550,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Blue Chip Partners Inc. raised its holdings in Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 15 shares during the last quarter. Jackson Grant Investment Advisers Inc. raised its holdings in Bristol-Myers Squibb by 0.4% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock worth $218,000 after acquiring an additional 15 shares during the last quarter. Chilton Investment Co. LLC raised its holdings in Bristol-Myers Squibb by 0.5% in the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock worth $294,000 after acquiring an additional 26 shares during the last quarter. Keel Point LLC raised its holdings in Bristol-Myers Squibb by 0.6% in the 2nd quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock worth $352,000 after acquiring an additional 39 shares during the last quarter. Finally, Hudock Capital Group LLC raised its holdings in Bristol-Myers Squibb by 0.4% in the 2nd quarter. Hudock Capital Group LLC now owns 11,775 shares of the biopharmaceutical company’s stock worth $656,000 after acquiring an additional 49 shares during the last quarter. Institutional investors own 69.56% of the company’s stock.

In other Bristol-Myers Squibb news, Director Theodore R. Samuels II acquired 4,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was purchased at an average price of $62.30 per share, with a total value of $249,200.00. Following the transaction, the director now directly owns 22,000 shares in the company, valued at approximately $1,370,600. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the business’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the sale, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The disclosure for this sale can be found here. Insiders own 0.23% of the company’s stock.

Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $63.87 on Wednesday. Bristol-Myers Squibb Co has a 1 year low of $51.56 and a 1 year high of $66.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. The stock has a market cap of $103,373.98, a price-to-earnings ratio of 108.25, a PEG ratio of 1.96 and a beta of 1.09.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 33.68%. The firm had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same quarter in the previous year, the firm posted $0.63 EPS. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. sell-side analysts forecast that Bristol-Myers Squibb Co will post 3.22 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Friday, January 5th were given a dividend of $0.40 per share. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date was Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.51%. Bristol-Myers Squibb’s payout ratio is presently 271.19%.

A number of equities research analysts have commented on BMY shares. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Vetr downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 target price for the company. in a research report on Thursday, December 28th. SunTrust Banks raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Monday, October 30th. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research report on Thursday, October 26th. Finally, Leerink Swann lifted their target price on shares of Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $65.58.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2018/02/14/bristol-myers-squibb-co-bmy-position-trimmed-by-investment-counsel-inc.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.